A Prospective Study of Calcaneal Bone Mineral Density in Acute Charcot Osteoarthropathy

Short running title: Fall of BMD in Charcot osteoarthropathy

Nina L Petrova, MD and Michael E Edmonds, FRCP

Diabetic Foot Clinic, King's College Hospital, London, UK

Corresponding author:
Dr Nina Petrova
E-mail: petrovanl@yahoo.com

Submitted 13 April 2010 and accepted 29 June 2010.

This is an uncopyedited electronic version of an article accepted for publication in Diabetes Care. The American Diabetes Association, publisher of Diabetes Care, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes Care in print and online at http://care.diabetesjournals.org.
Objective: To measure prospectively bone mineral density (BMD) of the Charcot and non-Charcot foot in 36 diabetic patients presenting with acute Charcot osteoarthropathy.

Research Design and Methods: Calcaneal BMD was measured with quantitative ultrasound at presentation, at 3 months of casting and then at the time of the clinical resolution.

Results: BMD of the Charcot foot was significantly reduced compared with BMD of the non-Charcot foot at presentation (p=0.001), at 3 months of casting (p<0.001) and at the time of clinical resolution (p<0.001). Overall, from the time of presentation to the time of resolution there was a significant fall of BMD of the Charcot foot (p<0.001) but not of the non-Charcot foot (p=0.439).

Conclusions: Although the Charcot foot was treated with casting until clinical resolution, there was a significant fall of BMD only from presentation up until 3 months of casting.

Studies on bone mineral density (BMD) have shown a reduction of BMD of the Charcot foot compared with the contralateral non-Charcot foot [1, 2, 3, 4]. However, it is not known what happens to BMD in the natural history of the osteoarthropathy. The aim of this study was to measure prospectively the longitudinal changes of BMD of the Charcot and non-Charcot foot in patients presenting with acute Charcot osteoarthropathy.

RESEARCH DESIGN AND METHODS

We studied 36 consecutive patients [19 type 1 diabetes; 20 males; mean age 54 years (49.4-57.9), mean (95% CI); mean duration of diabetes 22 years (16.9-26.3)] who presented to the Diabetic Foot Clinic between February 2002 and October 2008 with a red hot swollen foot and a skin temperature greater than 2°C compared with the contralateral foot and had no previous offloading treatment. Foot skin temperatures were measured by Dermatemp 1001 (Exergen, MA, USA). All patients were treated with offloading and cast immobilisation, until the temperature difference between the feet was less than 2°C at two consecutive monthly visits [5,6].

BMD of the calcaneum was measured by quantitative ultrasound (Sahara Clinical Bone Sonometer, Hologic Inc., Waltham, MA, USA) as described previously [1]. BMD of the Charcot foot was compared with BMD of the non-Charcot foot at presentation, at 3 months and at the time of the clinical resolution at the end of the casting treatment using paired t-test. One way repeated measures ANOVA was used to assess the longitudinal change of BMD and skin foot temperature difference between feet. Pairwise comparisons between the means for BMD at presentation, at 3 months and at clinical resolution were carried out to assess the effect of time. Results are presented as means (95% CI). Differences were considered significant at p<0.05.

All subjects gave informed written consent to participation. The study was approved by King’s College Hospital NHS Trust Research Ethics Committee and carried out in accordance with the Declaration of Helsinki.

RESULTS

At presentation, BMD of the Charcot foot was significantly reduced compared with BMD of the non-Charcot foot [0.456 g/cm² (0.411-0.502) versus 0.494 g/cm² (0.456-0.533), p=0.001], and also at 3 months of casting [0.433 g/cm² (0.389-0.476) versus 0.482 g/cm² (0.393-0.564), p<0.001] and at the time
of clinical resolution [0.432 g/cm$^2$ (0.388-0.477) versus 0.479 g/cm$^2$ (0.393-0.579), p<0.001].

Time to clinical resolution was 8.2 months (6.9-9.5). The multivariate analysis demonstrated a significant fall of BMD of the Charcot foot from the time of presentation to the time of clinical resolution (Wilks’s $\Lambda$ = 0.525, p<0.001). This was noted in both type 1 (Wilks’s $\Lambda$ = 0.528, p=0.006); (Figure 1A); and type 2 diabetes (Wilks’s $\Lambda$ = 0.497, p=0.015), (Figure 1B).

The pairwise comparisons between the different time points demonstrated a significant fall of BMD of the Charcot foot from presentation to clinical resolution (p=0.015). The fall of BMD from presentation [0.456 g/cm$^2$ (0.411-0.502)] to 3 months of casting [0.433 g/cm$^2$ (0.389-0.476)] was highly significant (p<0.001), both in type 1 (p=0.002) and type 2 diabetes (p=0.004), but the subsequent fall of BMD from 3 months casting to clinical resolution was not significant [0.433 g/cm$^2$ (0.389-0.476) to 0.432 g/cm$^2$ (0.388-0.477), p=0.949]. This applied to both type 1 (p=0.748) and type 2 diabetes (p=0.832).

In contrast to the Charcot foot, the multivariate analysis in the non-Charcot foot indicated that there was a non-significant fall of BMD from the time of presentation [0.494 g/cm$^2$ (0.456-0.533)] to the time of resolution [0.479 g/cm$^2$ (0.393-0.579)], Wilks’s $\Lambda$ = 0.947, p=0.439 and this was present in both type 1 (Wilks’s $\Lambda$ = 0.935, p=0.583), (Figure 1A) and type 2 diabetes (Wilks’s $\Lambda$ = 0.799, p=0.259), (Figure 1B).

There was a significant fall of the skin foot temperature difference between the Charcot and non-Charcot foot from the time of presentation to the time of resolution (Wilks’s $\Lambda$ = 0.423, p<0.001). The skin foot temperature difference also fell significantly from 3.5°C (3.1-4.1) at presentation to 2.2 °C (1.8-2.2) at 3 months of casting (p<0.001), and the latter further significantly reduced to 1.4 °C (1.1-1.8) at clinical resolution, (p=0.001).

**CONCLUSIONS**

This study demonstrated that from the time of presentation to clinical resolution that there was a significant fall of BMD of the Charcot foot but not of the non-Charcot foot. Although, there was a significant fall of BMD of the Charcot foot at 3 months of casting compared with BMD at presentation, there was no further significant reduction of BMD from 3 months casting up until clinical resolution, despite the ongoing casting of the Charcot foot.

Our study showed a fall of BMD at 3 months of casting in the Charcot foot both in type 1 and type 2 diabetes. The skin foot temperature of the Charcot foot was still 2°C greater compared with the non-Charcot foot and this may have been related to inflammatory osteolysis which would have resulted in a fall of BMD [4]. Increased levels of proinflammatory cytokines have been reported in patients with acute Charcot osteoarthropathy and this may explain this observed reduction of BMD [7,8,9].

However, this fall of BMD may have been aggravated by the cast immobilisation of the Charcot foot and a recent case report has documented a fall of BMD in a total contact cast, highlighting the effect of immobilisation [10]. In our study, although there was a significant fall of BMD of the Charcot foot from presentation to 3 months of casting, this was not followed by a further significant fall of BMD up until clinical resolution despite the ongoing casting. Thus, it is more likely that the overall fall of BMD was related to inflammatory osteolysis rather than casting immobilisation.

A limitation of this study is that we measured BMD of the calcaneum not BMD at the site of Charcot osteoarthropathy. Nevertheless, the calcaneum is a disease-responsive bone with high metabolic turnover rate [11], and should have reflected overall changes of BMD in the foot.
In conclusion, although the Charcot foot was treated with casting until clinical resolution, there was a significant fall of BMD only from presentation until 3 months of casting. This may be related to the inflammatory osteolysis of Charcot osteoarthropathy.

**Author Contributions:** N.P. researched data, contributed to discussion, wrote manuscript, reviewed/edited manuscript; M.E. researched data, contributed to discussion, wrote manuscript, reviewed/edited manuscript.

**ACKNOWLEDGMENTS:**
Dr NL Petrova was supported by Diabetes UK Grant: BDA: RD 01/002284 and grant BDA: 05/0003025. The authors declare no conflict of interest.

**REFERENCES:**
Figure 1. Longitudinal changes of BMD of the Charcot and non-Charcot foot in patients with type 1 diabetes (Figure 1A) and in patients with type 2 diabetes (Figure 1B)

Data are means (95% confidence intervals)
P-values indicate significance of the changes of BMD of the Charcot and non-Charcot foot from the time of presentation until the time of clinical resolution